Skip to main content
OpenTrials
Completed

NCT Number: NCT07334860

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine.

The goals of the trial are to learn:

* What happens to different forms of MK-1167 in a healthy person's body over time * About the safety of MK-1167 and if people tolerate it

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

QPS-MRA, LLC ( Site 0001)

South Miami, Florida, 33143, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is in good health
  • Has a body mass index (BMI) ≥18 and ≤ 32 kg/m^2, inclusive

Exclusion criteria

  • Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
  • Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.

Treatment and study plan

MK-1167

Drug

Oral administration

Primary outcomes

  1. Area Under the Curve from Time 0 to Infinity (AUC0-inf) of MK-1167

    Time frame: At designated time points (up to approximately 21 days)

    Blood samples will be collected to determine the AUC0-inf of MK-1167.

  2. Maximum Plasma Concentration (Cmax) of MK-1167

    Time frame: At designated time points (up to approximately 21 days)

    Blood samples will be collected to determine the Cmax of MK-1167.

  3. Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) of MK-1167

    Time frame: At designated time points (up to approximately 21 days)

    Blood samples will be collected to determine the AUC0-last of MK-1167.

Secondary outcomes

  1. Area Under the Curve from Time 0 to 24 hours (AUC0-24) of MK-1167

    Time frame: At designated time points (up to approximately 24 hours)

    Blood samples will be collected to determine the AUC0-24 of MK-1167.

  2. Concentration at 24 hours (C24) of MK-1167

    Time frame: At designated time points (up to approximately 24 hours)

    Blood samples will be collected to determine the C24 of MK-1167.

  3. Time to Maximum Serum Concentration (Tmax) of MK-1167

    Time frame: At designated time points (up to approximately 21 days)

    Blood samples will be collected to determine the Tmax of MK-1167.

  4. Apparent Terminal Half-life (t1/2) of MK-1167

    Time frame: At designated time points (up to approximately 21 days)

    Blood samples will be collected to determine the t1/2 of MK-1167.

  5. Apparent Clearance after Nonintravenous Administration (CL/F) of MK-1167

    Time frame: At designated time points (up to approximately 21 days)

    Blood samples will be collected to determine the CL/F of MK-1167.

  6. Apparent Volume of Distribution during Terminal Phase (Vz/F) of MK-1167

    Time frame: At designated time points (up to approximately 21 days)

    Blood samples will be collected to determine the Vz/F of MK-1167.

  7. Number of Participants Who Experience One or More Adverse Events (AEs)

    Time frame: Up to approximately 78 days

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

  8. Number of Participants Who Discontinue Study Intervention Due to an AE

    Time frame: Up to approximately 36 days

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Two-Period, Open-label, Fixed-Sequence Study to Evaluate the Single-Dose Pharmacokinetics of Two Formulations of MK-1167 in Healthy Participants

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 12, 2026
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.